P0DTC2 (SPIKE_SARS2) Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2)

Spike glycoprotein UniProtKBInterProInteractive Modelling

1273 aa; Sequence (Fasta) ; 2 identical sequences: Severe acute respiratory syndrome coronavirus 2: A0A6G7K2L4, A0A679G9E9

Available Structures

711 Experimental Structures

DescriptionOligo-stateLigandsStructureRange
SARS-CoV-2 spike protein in complex with ACE2, Beta variant, C2B state Heteromer
Q9BYF1;
14-1161
Assess
SARS-CoV-2 spike protein in complex with ACE2, Beta variant, C1 state Heteromer
Q9BYF1;
14-1161
Assess
SARS-CoV-2 spike protein in complex with ACE2, Beta variant, C2A state Heteromer
Q9BYF1;
14-1161
Assess
SARS-CoV-2 spike protein in complex with ACE2, Beta variant, C3 state Heteromer
Q9BYF1;
14-1161
Assess
Cryo-EM structure of SARS-CoV-2 spike in complex with neutralizing antibody A23-58.1 that targets t… Heteromer
NAG; 15×NAG;NAG; 27×NAG;14-1149
Assess
Cryo-EM structure of SARS-CoV-2 spike in complex with neutralizing antibody B1-182.1 that targets t… Heteromer
13×NAG;NAG; 27×NAG;14-1149
Assess
Beta-06 fab in complex with SARS-CoV-2 beta-Spike glycoprotein Heteromer
12×NAG; 28×NAG;13-1147
Assess
Beta-43 fab in complex with SARS-CoV-2 beta-Spike glycoprotein Heteromer
12×NAG; 29×NAG;13-1147
Assess
COVOX-222 fab in complex with SARS-CoV-2 beta-Spike glycoprotein Heteromer
12×NAG; 28×NAG;13-1147
Assess
Cryo-EM structure of NTD-directed neutralizing antibody 1-87 in complex with prefusion SARS-CoV-2 s… Heteromer
17×NAG;NAG; 34×NAG;14-1147
Assess
Cryo-EM structure of neutralizing antibody 1-57 in complex with prefusion SARS-CoV-2 spike glycopro… Heteromer
NAG; 18×NAG; 30×NAG;14-1147
Assess
S-2H2-F3a structure, two RBDs are up and one RBD is down, each RBD binds with a 2H2 Fab. Heteromer
14-1147
Assess
SARS-CoV-2 spike proteins trimer in complex with P17 and FC05 Fabs cocktail Heteromer
15×NAG; 16×NAG;14-1147
Assess
Cryo-EM structure of NTD-directed neutralizing antibody 5-24 in complex with prefusion SARS-CoV-2 s… Heteromer
16×NAG;NAG; 36×NAG;14-1147
Assess
EM structure of SARS-CoV-2 Spike glycoprotein (one RBD up) in complex with COVOX-159 Heteromer
15×NAG; 24×NAG;14-1147
Assess
S-2H2-F1 structure, one RBD is up and two RBDs are down, only up RBD binds with a 2H2 Fab Heteromer
14-1147
Assess
S-3C1-F1 structure, one RBD is up and two RBDs are down, the up RBD binds with a 3C1 fab Heteromer
14-1147
Assess
P17-H014 Fab cocktail in complex with SARS-CoV-2 spike protein Heteromer
15×NAG; 16×NAG;14-1147
Assess
SARS-CoV-2 Spike Proteins Trimer in Complex with FC05 and H014 Fabs Cocktail Heteromer
15×NAG; 16×NAG;14-1147
Assess
S-2H2-F2 structure, two RBDs are up and one RBD is down, each up RBD binds with a 2H2 Fab. Heteromer
14-1147
Assess
Cryo-EM structure of NTD-directed neutralizing antibody 4-18 in complex with prefusion SARS-CoV-2 s… Heteromer
24×NAG; 30×NAG;14-1147
Assess
Cryo-EM structure of NTD-directed neutralizing antibody 4-8 Fab in complex with SARS-CoV-2 S2P spike Heteromer
28×NAG;14-1147
Assess
SARS-CoV-2 S-ACE2 complex Heteromer
Q9BYF1;
18×NAG; 36×NAG;14-1147
Assess
S-2H2-F3b structure, three RBDs are up and each RBD binds with a 2H2 Fab. Heteromer
14-1147
Assess
SARS-CoV-2 spike protein and P17 fab complex with one RBD in close state Heteromer
27×NAG;14-1147
Assess
Complex of SARS-CoV-2 spike protein and Fab P17 with one RBD in open state and two RBD in closed st… Heteromer
14×NAG; 16×NAG;14-1147
Assess
S-3C1-F2 structure, two RBDs are up and one RBD is down, the two up RBD bind with a 3C1 fab. Heteromer
14-1147
Assess
S-3C1-F3a structure, two RBDs are up and one RBD is down, each RBD binds with a 3C1 fab. Heteromer
14-1147
Assess
Cryo-EM structure of NTD-directed neutralizing antibody 2-17 Fab in complex with SARS-CoV-2 S2P spi… Heteromer
26×NAG;14-1147
Assess
Cryo-EM structure of the SARS-CoV-2 N501Y mutant spike protein ectodomain bound to Fab ab1 (class 2) Heteromer
18×NAG; 24×NAG;14-1147
Assess
Cryo-EM structure of the SARS-CoV-2 N501Y mutant spike protein ectodomain bound to Fab ab1 (class 1) Heteromer
18×NAG; 24×NAG;14-1147
Assess
Cryo-EM structure of the SARS-CoV-2 N501Y mutant spike protein ectodomain bound to VH ab8 Heteromer
18×NAG; 24×NAG;14-1147
Assess
Cryo-EM structure of the SARS-CoV-2 N501Y mutant spike protein ectodomain bound to human ACE2 ectod… Heteromer
Q9BYF1;
18×NAG; 32×NAG;14-1147
Assess
SARS-CoV-2 Spike protein in complex with hb27 and fc05 Fab cocktail Heteromer
14×NAG;14-1147
Assess
S-3C1-F3b structure, all the three RBDs are in the up conformation and each of them associates with… Heteromer
14-1147
Assess
EM structure of SARS-CoV-2 Spike glycoprotein (all RBD down) in complex with COVOX-159 Heteromer
15×NAG; 24×NAG;14-1147
Assess
XG005-bound SARS-CoV-2 S Heteromer
45×NAG;14-1147
Assess
SARS-CoV-2 Kappa variant spike protein in complex with ACE2, state C2a Heteromer
Q9BYF1;
14-1147
Assess
Cryo-EM structure of the SARS-CoV-2 D614G mutant spike protein ectodomain bound to human ACE2 ectod… Heteromer
Q9BYF1;
18×NAG; 26×NAG;14-1147
Assess
Cryo-EM structure of SARS-CoV-2 Omicron spike protein in complex with human ACE2 Heteromer
Q9BYF1;
18×NAG; 34×NAG;14-1147
Assess
Cryo-EM structure of the SARS-CoV-2 D614G,N501Y,E484K mutant spike protein ectodomain bound to huma… Heteromer
Q9BYF1;
18×NAG; 26×NAG;14-1147
Assess
Cryo-EM structure of the SARS-CoV-2 D614G,N501Y,E484K,K417T mutant spike protein ectodomain bound t… Heteromer
Q9BYF1;
18×NAG; 28×NAG;14-1147
Assess
Cryo-EM structure of the SARS-CoV-2 D614G,L452R mutant spike protein ectodomain bound to human ACE2… Heteromer
Q9BYF1;
18×NAG; 28×NAG;14-1147
Assess
Cryo-EM structure of the SARS-CoV-2 D614G,N501Y,E484K,K417N mutant spike protein ectodomain bound t… Heteromer
Q9BYF1;
18×NAG; 42×NAG;14-1147
Assess
Cryo-EM structure of the SARS-CoV-2 D614G,N501Y mutant spike protein ectodomain bound to human ACE2… Heteromer
Q9BYF1;
18×NAG; 28×NAG;14-1147
Assess
SARS-CoV-2 Delta S-ACE2-C2a Heteromer
Q9BYF1;
14-1147
Assess
SARS-CoV-2 Delta S-8D3 Heteromer
14-1147
Assess
SARS-CoV-2 Delta S-ACE2-C1 Heteromer
Q9BYF1;
14-1147
Assess
SARS-CoV-2 Delta S-ACE2-C2b Heteromer
Q9BYF1;
14-1147
Assess
SARS-CoV-2 Delta S-ACE2-C3 Heteromer
Q9BYF1;
14-1147
Assess
Nanobody C5 bound to Spike Heteromer
15×NAG; 36×NAG;14-1147
Assess
SARS-CoV-2 S trimer with three-antibody cocktail complex Heteromer
15×NAG;14-1147
Assess
SARS-CoV-2 S trimer with four-antibody cocktail complex Heteromer
12×NAG;14-1147
Assess
SARS-CoV-2 Kappa variant spike protein in C3 state Heteromer
Q9BYF1;
14-1147
Assess
SARS-CoV-2 Kappa variant spike protein in C2b state Heteromer
Q9BYF1;
14-1147
Assess
SARS-CoV-2 spike in complex with the S304 neutralizing antibody Fab fragment Heteromer
12×NAG;NAG; 36×NAG;15-1147
Assess
S protein of SARS-CoV-2 in complex bound with 4A8 Heteromer
NAG; 23×NAG; 25×NAG;14-1146
Assess
Cryo-EM structure of the SARS-CoV-2 spike protein bound to neutralizing sybodies (Sb23) Heteromer
NAG; 45×NAG;14-1146
Assess
SARS-CoV-2 Spike Glycoprotein with 1 ACE2 Bound Heteromer
Q9BYF1;
23×NAG;ZN;14-1146
Assess
SARS-CoV-2 spike in complex with nanobodies E Heteromer
51×NAG;14-1146
Assess
SARS-CoV-2 Spike Glycoprotein with 1 ACE2 Bound and 1 RBD Erect in Clockwise Direction Heteromer
Q9BYF1;
14-1146
Assess
SARS-CoV-2 Spike Glycoprotein with 3 ACE2 Bound Heteromer
Q9BYF1;
14-1146
Assess
Cryo-EM structure of the SARS-CoV-2 spike protein bound to neutralizing nanobodies (Ty1) Heteromer
12×NAG; 39×NAG;14-1146
Assess
SARS-CoV-2 Spike Glycoprotein with 1 ACE2 Bound and 1 RBD Erect in Anticlockwise Direction Heteromer
Q9BYF1;
14-1146
Assess
Cryo-EM structure of the SARS-CoV-2 spike protein bound to neutralizing sybodies (Sb23) 2-up confor… Heteromer
NAG; 45×NAG;14-1146
Assess
SARS-CoV-2 Spike Glycoprotein with 2 ACE2 Bound Heteromer
Q9BYF1;
14-1146
Assess
Cryo-EM structure of the SARS-CoV-2 spike glycoprotein bound to Fab H4 Heteromer
NAG; 33×NAG;14-1146
Assess
SARS-CoV-spike bound to two neutralising nanobodies Heteromer
NAG; 42×NAG;14-1146
Assess
Trimeric SARS-CoV-2 spike ectodomain bound to P008_056 Fab Heteromer
25×NAG;BLA; 29×NAG;14-1146
Assess
SARS-CoV-2 spike glycoprotein:Fab 5A6 complex I Heteromer
23×NAG;14-1146
Assess
SARS-CoV-2 spike glycoprotein:Fab 3D11 complex Heteromer
14-1146
Assess
CryoEm structure of SARS-CoV-2 spike protein (S-6P, 1-up) in complex with sybodies (Sb45) Heteromer
19×NAG; 35×NAG;14-1146
Assess
CryoEM structure of SARS-CoV-2 spike protein (S-6P, 2-up) in complex with sybodies (Sb45) Heteromer
17×NAG; 30×NAG;14-1146
Assess
SARS-CoV-2 S-6P in complex with 9 Fabs Heteromer
14-1146
Assess
Cryo-EM structure of SARS-CoV-2 S-Kappa variant (B.1.617.1) in complex with Angiotensin-converting … Heteromer
Q9BYF1;
37×NAG; 13×NAG;14-1146
Assess
Cryo-EM structure of SARS-CoV-2 S-Kappa variant (B.1.617.1) in complex with Angiotensin-converting … Heteromer
Q9BYF1;
31×NAG; 13×NAG;14-1146
Assess
Structure of the SARS-CoV-2 S 6P trimer in complex with neutralizing antibody N-612-014 Heteromer
14-1146
Assess
Cryo-EM structure of SARS-CoV-2 S-Beta variant (B.1.351) in complex with Angiotensin-converting enz… Heteromer
Q9BYF1;
31×NAG; 17×NAG;14-1146
Assess
Cryo-EM structure of SARS-CoV-2 S-Gamma variant (P.1) in complex with Angiotensin-converting enzyme… Heteromer
Q9BYF1;
30×NAG; 29×NAG;14-1146
Assess
Cryo-EM structure of SARS-CoV-2 S-Delta variant (B.1.617.2) in complex with Angiotensin-converting … Heteromer
Q9BYF1;
43×NAG; 14×NAG;14-1146
Assess
Cryo-EM structure of SARS-CoV-2 S-Delta variant (B.1.617.2) in complex with Angiotensin-converting … Heteromer
Q9BYF1;
38×NAG; 16×NAG;14-1146
Assess
Cryo-EM structure of SARS-CoV-2 S-Gamma variant (P.1) in complex with Angiotensin-converting enzyme… Heteromer
Q9BYF1;
30×NAG;NAG; 19×NAG;14-1146
Assess
Cryo-EM structure of SARS-CoV-2 S-Delta variant (B.1.617.2) in complex with Angiotensin-converting … Heteromer
Q9BYF1;
37×NAG; 15×NAG;14-1146
Assess
Cryo-EM structure of SARS-CoV-2 S-Gamma variant (P.1) in complex with Angiotensin-converting enzyme… Heteromer
Q9BYF1;
29×NAG; 26×NAG;14-1146
Assess
Structure of the SARS-CoV-2 spike glycoprotein in complex with a human single domain antibody n3113… Heteromer
NAG; 12×NAG; 18×NAG;14-1146
Assess
Structure of the SARS-CoV-2 spike glycoprotein in complex with a human single domain antibody n3113… Heteromer
16×NAG; 20×NAG;14-1146
Assess
Structure of the SARS-CoV-2 spike glycoprotein in complex with a human single domain antibody n3113… Heteromer
20×NAG;NAG; 21×NAG;14-1146
Assess
SARS-CoV-2 Kappa variant spike protein in complex wth ACE2, state C1 Heteromer
Q9BYF1;
14-1146
Assess
Beta-26 fab in complex with SARS-CoV-2 beta-Spike glycoprotein Heteromer
13×NAG; 31×NAG;15-1147
Assess
SARS-CoV-2 S/S2M11/S2M28 Global Refinement Heteromer
NAG;NAG; 45×NAG;14-1145
Assess
SARS-CoV-2 S/S2M11/S2X333 Global Refinement Heteromer
NAG;NAG; 45×NAG;14-1145
Assess
Cryo-EM structure of NTD-directed neutralizing antibody 5-7 in complex with prefusion SARS-CoV-2 sp… Heteromer
NAG; 48×NAG;14-1145
Assess
SARS-CoV-2 S B.1.617.1 kappa variant + S309 + S2L20 Global Refinement Heteromer
51×NAG;14-1145
Assess
SARS-CoV-2 S B.1.617.2 delta variant + S2M11 + S2L20 Global Refinement Heteromer
NAG; 45×NAG;14-1145
Assess
SARS-CoV-2 S B.1.617.1 kappa variant + S2X303 Global Refinement Heteromer
NAG; 51×NAG;14-1145
Assess
SARS-CoV-2 S/S2M11/S2L28 Global Refinement Heteromer
NAG;NAG;NAG; 39×NAG;14-1144
Assess
CryoEM structure of neutralizing nanobody Nb12 in complex with SARS-CoV2 spike Heteromer
NAG; 13×NAG; 22×NAG;23-1150
Assess
cryo-EM structure of SARS-CoV-2 spike in complex with Fab 15033-7, three RBDs bound Heteromer
21×NAG;NAG; 18×NAG;14-1140
Assess
Beta-50 fab in complex with SARS-CoV-2 beta-Spike glycoprotein Heteromer
NAG; 14×NAG;NAG; 25×NAG;21-1147
Assess
SARS-CoV-2 spike in complex with the S2M11 neutralizing antibody Fab fragment Heteromer
18×NAG;NAG; 30×NAG;15-1140
Assess
Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragmen… Heteromer
NAG; 32×NAG;15-1140
Assess
Structure of the SARS-CoV-2 S 6P trimer in complex with neutralizing antibody C051 Heteromer
NAG; 27×NAG;15-1140
Assess
Structure of the SARS-CoV-2 S 6P trimer in complex with neutralizing antibody C548 Heteromer
NAG;NAG;NAG;NAG; 26×NAG;15-1140
Assess
Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting no… Heteromer
23-1148
Assess
Beta049 fab in complex with SARS-CoV2 beta-Spike glycoprotein, The Beta mAb response underscores th… Heteromer
NAG; 14×NAG;NAG; 26×NAG;22-1147
Assess
cryo-EM structure of SARS-CoV-2 spike in complex with Fab 15033-7, two RBDs bound Heteromer
NAG;NAG; 25×NAG;14-1138
Assess
SARS-CoV-2 spike protein in complex with Fab 15033-7, 2-"up"-1-"down" conformation Heteromer
12×NAG;NAG; 16×NAG;14-1137
Assess
SARS-CoV-2 spike in complex with LCB1 (2RBDs open) Heteromer
13×NAG; 33×NAG;27-1150
Assess
Cryo-EM structure of triple ACE2-bound SARS-CoV-2 trimer spike at pH 7.4 Heteromer
Q9BYF1;
NAG; 55×NAG;26-1149
Assess
Cryo-EM Structure of Double ACE2-Bound SARS-CoV-2 Trimer Spike at pH 5.5 Heteromer
Q9BYF1;
NAG; 48×NAG;26-1149
Assess
Cryo-EM structure of Triple ACE2-bound SARS-CoV-2 Trimer Spike at pH 5.5 Heteromer
Q9BYF1;
NAG; 56×NAG;26-1149
Assess
SARS-CoV-2 spike protein in complex with Fab 15033-7, 3-"up", asymmetric Heteromer
NAG;NAG;NAG;14-1137
Assess
Cryo-EM structure of double ACE2-bound SARS-CoV-2 trimer Spike at pH 7.4 Heteromer
Q9BYF1;
NAG; 53×NAG;26-1149
Assess
CryoEM structure of neutralizing nanobody Nb30 in complex with SARS-CoV2 spike Heteromer
11×NAG;NAG;NAG; 29×NAG;26-1149
Assess
SARS-CoV-2 spike protein in complex with sybodyb#15 in a 1up/1up-out/1down conformation. Heteromer
NAG;NAG;NAG;NAG; 19×NAG;26-1149
Assess
SARS-CoV-2 spike protein in complex with sybody#68 in a 2up/1flexible conformation Heteromer
10×NAG;NAG;NAG;NAG; 28×NAG;26-1149
Assess
SARS-CoV-2 spike protein in complex with sybody#15 and sybody#68 in a 1up/1up-out/1down conformation Heteromer
11×NAG;NAG;NAG; 19×NAG;26-1149
Assess
SARS-CoV-2 spike protein in complex with sybody#15 and sybody#68 in a 3up conformation Heteromer
10×NAG;NAG;NAG;NAG; 29×NAG;26-1149
Assess
Cryo-EM structure of broadly neutralizing antibody 2-36 in complex with prefusion SARS-CoV-2 spike … Heteromer
16×NAG;NAG;24-1147
Assess
Cryo-EM structure of single ACE2-bound SARS-CoV-2 trimer spike at pH 7.4 Heteromer
Q9BYF1;
NAG; 46×NAG;26-1148
Assess
Cryo-EM structure of single ACE2-bound SARS-CoV-2 trimer spike at pH 5.5 Heteromer
Q9BYF1;
NAG; 44×NAG;26-1148
Assess
SARS-CoV-2 S trimer with three RBD in the open state and complexed with three H014 Fab Heteromer
15×NAG; 30×NAG;25-1147
Assess
SARS-CoV-2 S trimer with two RBDs in the open state and complexed with two H014 Fab Heteromer
15×NAG; 30×NAG;25-1147
Assess
Complex of SARS-CoV-2 spike trimer with its neutralizing antibody HB27 Heteromer
15×NAG; 29×NAG;25-1147
Assess
SARS-CoV-2 S trimer with one RBD in the open state and complexed with one H014 Fab. Heteromer
15×NAG; 30×NAG;25-1147
Assess
CryoEM structure of SARS-CoV-2 Spike in complex with Nb17 Heteromer
25-1147
Assess
SARS-CoV-2 spike in prefusion state Heteromer
16×NAG;NAG;NAG; 18×NAG;MAN;DMS;27-1148
Assess
Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting no… Heteromer
27-1148
Assess
Cryo-EM Structure of SARS-CoV-2 Spike : H11-D4 Nanobody Complex Heteromer
20×NAG; 26×NAG;27-1147
Assess
EM structure of SARS-CoV-2 Spike glycoprotein in complex with COVOX-253H165L Fab Heteromer
10×NAG;NAG; 27×NAG;27-1147
Assess
SARS-CoV-2 Spike Glycoprotein with two ACE2 Bound Heteromer
Q9BYF1;
20×NAG; 40×NAG;27-1147
Assess
Cryo-EM structure of prefusion SARS-CoV-2 spike glycoprotein in complex with 910-30 Fab Heteromer
12×NAG; 35×NAG;27-1147
Assess
EM structure of SARS-CoV-2 Spike glycoprotein in complex with COVOX-40 Fab Heteromer
11×NAG; 27×NAG;27-1147
Assess
SARS-CoV-2 Spike in complex with neutralizing nanobody Nb6 Heteromer
12×NAG; 30×NAG;27-1147
Assess
Structure of the SARS-CoV-2 spike glycoprotein in complex with the C105 neutralizing antibody Fab f… Heteromer
NAG;NAG;NAG;NAG; 30×NAG;27-1147
Assess
SARS-CoV-2 Spike Glycoprotein with three ACE2 Bound Heteromer
Q9BYF1;
24×NAG; 42×NAG;27-1147
Assess
Structure of the SARS-CoV-2 spike glycoprotein in complex with the C105 neutralizing antibody Fab f… Heteromer
NAG;NAG;NAG; 24×NAG;27-1147
Assess
Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragmen… Heteromer
15×NAG; 27×NAG;27-1147
Assess
EM structure of SARS-CoV-2 Spike glycoprotein (one RBD up) in complex with COVOX-253H55L Fab Heteromer
10×NAG;NAG; 27×NAG;27-1147
Assess
Cryo-EM structure of SARS-CoV-2 2P S ectodomain bound to two copies of domain-swapped antibody 2G12 Heteromer
NAG;NAG;NAG;NAG; 25×NAG;27-1147
Assess
EM structure of SARS-CoV-2 Spike glycoprotein (all RBD down) in complex with COVOX-253H55L Fab Heteromer
14×NAG;NAG; 32×NAG;27-1147
Assess
Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragmen… Heteromer
10×NAG; 21×NAG;27-1147
Assess
SARS-CoV-2 Spike Glycoprotein with one ACE2 Bound Heteromer
Q9BYF1;
17×NAG; 36×NAG;27-1147
Assess
EM structure of SARS-CoV-2 Spike glycoprotein in complex with COVOX-150 Fab Heteromer
11×NAG; 27×NAG;27-1147
Assess
Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragmen… Heteromer
NAG;NAG;27-1147
Assess
EM structure of SARS-CoV-2 Spike glycoprotein in complex with COVOX-384 Fab Heteromer
15×NAG; 30×NAG;27-1147
Assess
SARS-CoV-2 Spike Protein Trimer bound to DH1043 fab Heteromer
27-1147
Assess
EM structure of SARS-CoV-2 Spike glycoprotein in complex with COVOX-40 Fab Heteromer
11×NAG; 27×NAG;27-1147
Assess
SARS-CoV-2 Spike glycoprotein in complex with a neutralizing antibody EY6A Fab Heteromer
13×NAG; 23×NAG;27-1147
Assess
Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragmen… Heteromer
15×NAG; 30×NAG;27-1147
Assess
Cryo-EM structure of SARS-CoV-2 2P S ectodomain bound to one copy of domain-swapped antibody 2G12 Heteromer
10×NAG;NAG;NAG;NAG; 31×NAG;27-1147
Assess
EM structure of SARS-CoV-2 Spike glycoprotein in complex with COVOX-88 Fab Heteromer
15×NAG;NAG;NAG; 30×NAG;27-1147
Assess
SARS-CoV-2 Spike in complex with neutralizing nanobody mNb6 Heteromer
18×NAG; 27×NAG;27-1147
Assess
Cryo-EM structure of SARS-CoV-2 2P S ectodomain bound domain-swapped antibody 2G12 from masked 3D r… Heteromer
10×NAG;NAG;NAG;NAG; 32×NAG;27-1147
Assess
EM structure of SARS-CoV-2 Spike glycoprotein in complex with COVOX-316 Fab Heteromer
15×NAG;NAG; 25×NAG;27-1147
Assess
SARS CoV2 Spike ectodomain with engineered trimerized VH binder Heteromer
27-1147
Assess
Structure of SARS-CoV-2 S protein in complex with Receptor Binding Domain antibody DH1041 Heteromer
11×NAG;NAG; 17×NAG;27-1147
Assess
Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragmen… Heteromer
13×NAG; 34×NAG;27-1147
Assess
Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragmen… Heteromer
13×NAG;NAG;NAG; 33×NAG;27-1147
Assess
Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragmen… Heteromer
28×NAG;27-1147
Assess
Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragmen… Heteromer
NAG;NAG;NAG; 26×NAG;27-1147
Assess
Structure of the SARS-CoV-2 spike glycoprotein in complex with the 47D11 neutralizing antibody Fab … Heteromer
10×NAG;NAG;NAG;NAG;NAG;MAN; 28×NAG;FUC;MAN;27-1147
Assess
Spike protein from SARS-CoV2 with Fab fragment of enhancing antibody 8D2 Heteromer
27-1147
Assess
Spike protein from SARS-CoV2 with Fab fragment of enhancing antibody 2490 Heteromer
27-1147
Assess
Mink Cluster 5-associated SARS-CoV-2 spike protein(S-GSAS-D614G-delFV) missing the S1 subunit and S… Heteromer
NAG; 27×NAG;27-1147
Assess
SARS-CoV-2 Spike in complex with neutralizing Fab SARS2-38 (three down conformation) Heteromer
15×NAG; 33×NAG;27-1147
Assess
Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting no… Heteromer
27-1147
Assess
Cryo-EM structure of SARS-CoV-2 S-UK variant (B.1.1.7) in complex with Angiotensin-converting enzym… Heteromer
29×NAG; 26×NAG;27-1147
Assess
Ultrapotent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutat… Heteromer
22×NAG;27-1147
Assess
Ultrapotent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutat… Heteromer
20×NAG;27-1147
Assess
SARS-CoV-2 Spike in complex with neutralizing Fab 2B04 (one up, two down conformation) Heteromer
14×NAG; 21×NAG;NAG;NAG;NAG;27-1147
Assess
SARS-CoV-2 Spike in complex with neutralizing Fab 2H04 (three down conformation) Heteromer
12×NAG; 21×NAG;NAG;NAG;NAG;NAG;27-1147
Assess
Structure of human SARS-CoV-2 spike glycoprotein trimer bound by neutralizing antibody C1C-A3 Fab (… Heteromer
NAG; 45×NAG;27-1147
Assess
Beta-32 fab in complex with SARS-CoV-2 beta-Spike glycoprotein Heteromer
15×NAG; 30×NAG;27-1147
Assess
SARS-CoV-2 B.1.1.7 S-ACE2 complex Heteromer
Q9BYF1;
16×NAG; 27×NAG;27-1147
Assess
Beta-53 fab in complex with SARS-CoV-2 beta-Spike glycoprotein Heteromer
NAG; 11×NAG; 15×NAG;27-1147
Assess
Structure of SARS-CoV-2 S protein in complex with N-terminal domain antibody DH1052 Heteromer
14×NAG; 31×NAG;27-1147
Assess
Structure of SARS-CoV-2 S protein in complex with N-terminal domain antibody DH1050.1 Heteromer
15×NAG; 33×NAG;27-1147
Assess
Structure of SARS-CoV-2 S protein in complex with Receptor Binding Domain antibody DH1047 Heteromer
13×NAG;NAG; 24×NAG;27-1147
Assess
H11-H4 bound to Spike Heteromer
20×NAG; 26×NAG;27-1147
Assess
Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragmen… Heteromer
28×NAG;27-1147
Assess
Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragmen… Heteromer
23×NAG;27-1147
Assess
S protein of SARS-CoV-2 in complex bound with P5A-3C12_2B Heteromer
22×NAG; 26×NAG;27-1146
Assess
SARS-CoV 2 Spike Protein bound to LY-CoV555 Heteromer
NAG; 16×NAG;27-1146
Assess
S protein of SARS-CoV-2 in complex bound with P5A-3C12_1B Heteromer
21×NAG; 27×NAG;27-1146
Assess
Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragmen… Heteromer
33×NAG;27-1146
Assess
SARS-CoV-2 spike in complex with LCB3 (2RBDs open) Heteromer
13×NAG; 33×NAG;27-1146
Assess
Cryo-EM structure of the SARS-CoV-2 S-6P in complex with BD-368-2 Fabs Heteromer
NAG; 31×NAG;27-1146
Assess
BD23-Fab in complex with the S ectodomain trimer Heteromer
NAG;NAG; 32×NAG;27-1146
Assess
S protein of SARS-CoV-2 in complex bound with T-ACE2 Heteromer
Q9BYF1;
35×NAG; 34×NAG;27-1146
Assess
S protein of SARS-CoV-2 in complex bound with P5A-3A1 Heteromer
22×NAG; 26×NAG;27-1146
Assess
Cryo-EM structure of the SARS-CoV-2 spike glycoprotein bound to Fab 2-4 Heteromer
NAG;NAG;NAG; 36×NAG;27-1146
Assess
Conformation 1 of S-ACE2-B0AT1 ternary complex Heteromer
Q695T7; Q9BYF1;
58×NAG; 64×NAG;LEU;ZN;27-1146
Assess
Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragmen… Heteromer
11×NAG; 26×NAG;27-1146
Assess
Trypsin-digested S protein of SARS-CoV-2 bound with PD of ACE2 in the conformation 1 (1 up RBD and … Heteromer
Q9BYF1;
27×NAG; 28×NAG;27-1146
Assess
S protein of SARS-CoV-2 bound with PD of ACE2 in the conformation 2 (1 up RBD and 1 PD bound) Heteromer
Q9BYF1;
26×NAG; 30×NAG;27-1146
Assess
S protein of SARS-CoV-2 bound with PD of ACE2 in the conformation 3 (2 up RBD and 1 PD bound) Heteromer
Q9BYF1;
27×NAG; 28×NAG;27-1146
Assess
Trypsin-digested S protein of SARS-CoV-2 bound with PD of ACE2 in the conformation 3 (3 up RBD and … Heteromer
Q9BYF1;
32×NAG; 29×NAG;27-1146
Assess
Trypsin-digested S protein of SARS-CoV-2 bound with PD of ACE2 in the conformation 2 (2 up RBD and … Heteromer
Q9BYF1;
32×NAG; 29×NAG;27-1146
Assess
Cryo-EM structure of SARS-CoV-2 spike in complex with a neutralizing antibody RBD-chAb-25 Heteromer
27×NAG; 21×NAG;27-1146
Assess
Cryo-EM structure of SARS-CoV-2 spike in complex with a neutralizing antibody RBD-chAb-45 Heteromer
24×NAG; 24×NAG;27-1146
Assess
Structure of the SARS-CoV-2 S 6P trimer in complex with neutralizing antibody C032 Heteromer
NAG;NAG; 22×NAG;27-1146
Assess
S protein of SARS-CoV-2 in complex bound with P5A-2G9 Heteromer
21×NAG; 28×NAG;27-1146
Assess
S protein of SARS-CoV-2 in complex bound with P5A-1B9 Heteromer
19×NAG; 33×NAG;27-1146
Assess
S protein of SARS-CoV-2 in complex bound with P5A-1B6_2B Heteromer
21×NAG; 28×NAG;27-1146
Assess
S protein of SARS-CoV-2 in complex bound with P5A-2F11_2B Heteromer
21×NAG;NAG; 28×NAG;27-1146
Assess
S protein of SARS-CoV-2 in complex bound with P5A-1B8_2B Heteromer
20×NAG; 30×NAG;27-1146
Assess
S protein of SARS-CoV-2 in complex bound with P5A-1B8_3B Heteromer
20×NAG; 31×NAG;27-1146
Assess
S protein of SARS-CoV-2 in complex bound with P5A-2G7 Heteromer
21×NAG; 28×NAG;27-1146
Assess
S protein of SARS-CoV-2 in complex bound with FabP5A-1B8 Heteromer
21×NAG; 28×NAG;27-1146
Assess
S protein of SARS-CoV-2 in complex bound with FabP5A-2G7 Heteromer
20×NAG; 29×NAG;27-1146
Assess
S protein of SARS-CoV-2 in complex bound with P2B-1A10 Heteromer
21×NAG; 28×NAG;27-1146
Assess
S protein of SARS-CoV-2 in complex bound with P2B-1A1 Heteromer
23×NAG; 28×NAG;27-1146
Assess
S protein of SARS-CoV-2 in complex bound with P5A-1B6_3B Heteromer
20×NAG; 31×NAG;27-1146
Assess
S protein of SARS-CoV-2 in complex bound with P5A-2F11_3B Heteromer
22×NAG;NAG; 27×NAG;27-1146
Assess
Cryo-EM structure of SARS-CoV-2 S-D614G variant in complex with neutralizing antibodies, RBD-chAb15… Heteromer
27×NAG; 21×NAG;27-1146
Assess
Structure of the SARS-CoV-2 S 6P trimer in complex with neutralizing antibody N-612-017 Heteromer
NAG; 19×NAG;27-1146
Assess
S protein of SARS-CoV-2 in complex bound with P36-5D2 (state1) Heteromer
27-1146
Assess
S protein of SARS-CoV-2 in complex bound with P36-5D2(state2) Heteromer
17×NAG; 28×NAG;27-1146
Assess
SARS-CoV-2 Spike trimer in complex with XG014 Fab Heteromer
24×NAG;27-1146
Assess
SARS-CoV-2 spike in complex with the S2H13 neutralizing antibody (closed conformation) Heteromer
12×NAG; 36×NAG;27-1145
Assess
SARS-CoV-2 spike in complex with the S2E12 neutralizing antibody Fab fragment Heteromer
15×NAG; 33×NAG;27-1145
Assess
SARS-CoV-2 spike in complex with the S2A4 neutralizing antibody Fab fragment Heteromer
12×NAG;NAG; 33×NAG;27-1145
Assess
SARS-CoV-2 spike in complex with the S2H13 neutralizing antibody (one RBD open) Heteromer
11×NAG; 36×NAG;27-1145
Assess
Structure of the SARS-CoV-2 S 6P trimer in complex with the ACE2 protein decoy, CTC-445.2 (State 4) Heteromer
NAG; 27×NAG;27-1145
Assess
Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragmen… Heteromer
15×NAG; 33×NAG;27-1145
Assess
SARS-CoV-2 S (B.1.429 / epsilon variant) + S2M11 + S2L20 Global Refinement Heteromer
NAG;NAG; 39×NAG;27-1145
Assess
SARS-CoV-2 S glycoprotein in complex with S2X259 Fab Heteromer
12×NAG; 30×NAG;27-1145
Assess
Structure of the SARS-CoV-2 S 6P trimer in complex with neutralizing antibody C118 (State 1) Heteromer
39×NAG;27-1145
Assess
Cryo-EM structure of the SARS-CoV-2 spike glycoprotein bound to Fab 2-7 Heteromer
NAG; 30×NAG;27-1144
Assess
Cryo-EM structure of the SARS-CoV-2 spike glycoprotein bound to Fab 2-43 Heteromer
NAG;NAG; 31×NAG;27-1144
Assess
Cryo-EM structure of the SARS-CoV-2 spike glycoprotein bound to Fab 2-15 Heteromer
NAG;NAG;NAG; 31×NAG;27-1144
Assess
SARS-CoV-2 spike in complex with the S2K146 neutralizing antibody Fab fragment (two receptor-bindin… Heteromer
NAG; 37×NAG;26-1141
Assess
Structure of the SARS-CoV-2 spike glycoprotein in complex with the S309 neutralizing antibody Fab f… Heteromer
12×NAG;NAG; 33×NAG;27-1140
Assess
Structure of the SARS-CoV-2 spike glycoprotein in complex with the S309 neutralizing antibody Fab f… Heteromer
10×NAG;NAG;NAG; 35×NAG;27-1140
Assess
Major cryo-EM structure of S protein trimer of SARS-CoV2 with K-874, composite map Heteromer
27-1138
Assess
Minor cryo-EM structure of S protein trimer of SARS-CoV2 with K-874A VHH, composite map Heteromer
27-1138
Assess
Structure of the SARS-CoV-2 S1 subunit in complex with antibody N-612-004 Heteromer
12-700
Assess
Dissociated S1 domain of SARS-CoV-2 Spike bound to ACE2 (Unmasked Refinement) Heteromer
Q9BYF1;
NAG;NAG;ZN;14-676
Assess
Complex of SARS-CoV-2 spike and CR3022 Fab (Homogeneous Refinement) Heteromer
NAG;33-676
Assess
Complex of SARS-CoV-2 spike and CR3022 Fab (Non-Uniform Refinement) Heteromer
NAG;33-579
Assess
SARS-CoV-2 Spike (2P) in complex with G32R7 Fab (RBD and NTD local reconstruction) Heteromer
NAG;NAG;NAG;14-528
Assess
SARS-CoV-2 NTD in complex with N9 Fab Heteromer
14-526
Assess
Local CryoEM structure of the SARS-CoV-2 S6PV2 in complex with BD-813 Fab and BD-744 Fab Heteromer
28-516
Assess
Local CryoEM structure of the SARS-CoV-2 S6PV2 in complex with BD-804 Fab Heteromer
NAG;28-516
Assess
Local CryoEM of the SARS-CoV-2 S6PV2 in complex with BD-667 Heteromer
NAG;28-516
Assess
Structure of viral peptides IPB19/N52 Heteromer
908-1201
Assess
Crystal structure of the N-terminal domain of SARS-CoV-2 beta variant spike glycoprotein in complex… Heteromer
NAG;NAG;NAG;CL;PEG;GOL;PO4;NAG;PG4;13-305
Assess
SARS-CoV-2 S NTD B.1.617.1 kappa variant S2L20 Local Refinement Heteromer
NAG;NAG;14-306
Assess
SARS-CoV-2 S NTD B.1.617.2 delta variant + S2L20 Local Refinement Heteromer
NAG;NAG;14-306
Assess
Crystal structure of SARS-CoV-2 S NTD bound to S2M28 Fab Heteromer
NAG;NAG;NAG;NAG;UNX;XYL;SO4;14-305
Assess
SARS-CoV-2 S NTD B.1.617.1 kappa variant S2X303 Local Refinement Heteromer
NAG;NAG;14-305
Assess
SARS-CoV2 spike glycoprotein N-terminal heptad repeat domain + SARS-CoV2(QEYKKEKE) Heteromer
914-1203
Assess
Crystallographic structure of neutralizing antibody 2-51 in complex with SARS-CoV-2 spike N-termina… Heteromer
NAG;NAG; 23×CA;ACT;PGE;14-303
Assess
SARS-CoV-2 S (B.1.429 / epsilon variant) + S2M11 + S2L20 (Local Refinement of the NTD/S2L20) Heteromer
NAG;27-306
Assess
SARS-CoV-2 Spike Protein N terminal domain in Complex with N11 Fab Heteromer
13-290
Assess
A proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2 Heteromer
14-290
Assess
SARS-CoV-2 Spike (2P) in complex with C12C9 Fab (NTD local reconstruction) Heteromer
NAG;14-290
Assess
Dissociated S1 domain of SARS-CoV-2 Spike bound to ACE2 (Non-Uniform Refinement) Heteromer
Q9BYF1;
NAG;NAG;ZN;322-590
Assess
SARS-CoV-2 S-NTD + Fab CM25 Heteromer
14-270
Assess
SARS-CoV-2 S/S2M11/S2M28 Local Refinement Heteromer
NAG;NAG;14-267
Assess
SARS-CoV-2 S/S2M11/S2L28 Local Refinement Heteromer
NAG;NAG;14-265
Assess
SARS-CoV-2 S/S2M11/S2X333 Local Refinement Heteromer
NAG;NAG;14-251
Assess
Structure of human SARS-CoV-2 neutralizing antibody C1C-A3 Fab Heteromer
NAG;NAG;319-541
Assess
Structure of SARS-CoV-2 spike protein receptor binding domain in complex with a neutralizing antibo… Heteromer
NAG;321-537
Assess
SARS-CoV-2 Spike:Fab 3D11 complex focused refinement Heteromer
NAG;329-537
Assess
SARS-CoV-2 Spike:5A6 Fab complex I focused refinement Heteromer
NAG;329-537
Assess
Structure of SARS-CoV-2 spike protein receptor binding domain in complex with a potent neutralizing… Heteromer
NAG;326-532
Assess
immune complex of SARS-CoV-2 RBD and cross-neutralizing antibody 7D6 Heteromer
NAG;NAG;324-527
Assess
Crystal structure of the SARS-CoV-2 RBD in complex with a human single domain antibody n3113 Heteromer
NAG;328-531
Assess
Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immuni… Heteromer
Q9BYF1;
NAG;CL;SO4;NA;PG5;ZN;NAG;PGE;329-531
Assess
Structure of sybody SR31 in complex with the SARS-CoV-2 S Receptor Binding domain (RBD) Heteromer
NAG; 13×FMT;GOL;ACT;330-531
Assess
Cryo-EM structure of the SARS-CoV-2 N501Y mutant spike protein ectodomain bound to human ACE2 ectod… Heteromer
Q9BYF1;
NAG;330-530
Assess
Cryo-EM structure of SARS-CoV-2 spike in complex with a neutralizing antibody chAb-45 (Focused refi… Heteromer
330-530
Assess
Cryo-EM structure of SARS-CoV-2 spike in complex with a neutralizing antibody chAb-25 (Focused refi… Heteromer
330-530
Assess
Local refinement of SARS-CoV-2 S-Delta variant (B.1.617.2) RBD and Angiotensin-converting enzyme 2 … Heteromer
Q9BYF1;
NAG;NAG;NAG;330-530
Assess
Local refinement of SARS-CoV-2 S-Beta variant (B.1.351) RBD and Angiotensin-converting enzyme 2 (AC… Heteromer
Q9BYF1;
NAG;NAG;330-530
Assess
Local refinement of SARS-CoV-2 S-Gamma variant (P.1) RBD and Angiotensin-converting enzyme 2 (ACE2)… Heteromer
Q9BYF1;
NAG;NAG;330-530
Assess
Local refinement of SARS-CoV-2 S-Kappa variant (B.1.617.1) RBD and Angiotensin-converting enzyme 2 … Heteromer
Q9BYF1;
NAG;NAG;NAG;330-530
Assess
Cryo-EM structure of the SARS-CoV-2 D614G,L452R mutant spike protein ectodomain bound to human ACE2… Heteromer
Q9BYF1;
NAG;330-530
Assess
Cryo-EM structure of SARS-CoV-2 Omicron spike protein in complex with human ACE2 (focused refinemen… Heteromer
Q9BYF1;
NAG;330-530
Assess
Cryo-EM structure of the SARS-CoV-2 D614G,N501Y,E484K,K417T mutant spike protein ectodomain bound t… Heteromer
Q9BYF1;
NAG;330-530
Assess
Cryo-EM structure of the SARS-CoV-2 D614G,N501Y,E484K mutant spike protein ectodomain bound to huma… Heteromer
Q9BYF1;
NAG;330-530
Assess
Cryo-EM structure of the SARS-CoV-2 D614G mutant spike protein ectodomain bound to human ACE2 ectod… Heteromer
Q9BYF1;
NAG;330-530
Assess
Cryo-EM structure of the SARS-CoV-2 D614G,N501Y mutant spike protein ectodomain bound to human ACE2… Heteromer
Q9BYF1;
NAG;330-530
Assess
Cryo-EM structure of the SARS-CoV-2 D614G,N501Y,E484K,K417N mutant spike protein ectodomain bound t… Heteromer
Q9BYF1;
NAG;330-530
Assess
Crystal structure of the SARS-CoV-2 receptor binding domain in complex with CR3022 Fab Heteromer
DMS;MLI;NAG;1PE;330-529
Assess
SARS-CoV-2 RBD in complex with Fab 15033-7 Heteromer
NAG;329-528
Assess
SARS-CoV-2 RBD in complex with Fab 15033 Heteromer
NAG;329-528
Assess
A neutralizing MAb targeting receptor-binding-domain of SARS-CoV-2 Heteromer
NAG;333-532
Assess
SARS-CoV-2 S RBD B.1.617.1 kappa variant S309 Local Refinement Heteromer
NAG;NAG;329-528
Assess
Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody CC12.3 Heteromer
NAG;334-532
Assess
SARS-CoV-2 spike receptor-binding domain (RBD) in complex with S2E12 Fab, S309 Fab, and S304 Fab Heteromer
NAG;CL;330-528
Assess
Structure of SARS-CoV-2 spike RBD in complex with cyclic peptide Heteromer
NAG;328-526
Assess
Structure of sybody MR17-SR31 fusion in complex with the SARS-CoV-2 S Receptor Binding domain (RBD) Heteromer
NAG;GOL; 14×ACT;1PE;BU2; 17×CD;334-531
Assess
Nanobody F2 bound to RBD Heteromer
NAG;331-528
Assess
SARS-CoV-2 spike receptor-binding domain with a G485R mutation in complex with human ACE2 Heteromer
Q9BYF1;
NAG;NAG;EDO;ZN;333-530
Assess
Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by st… Heteromer
NAG;332-529
Assess
Structure of the SARS-CoV-2 RBD in complex with neutralizing antibody N-612-056 Heteromer
NAG;331-528
Assess
Nanobody H3 AND C1 bound to RBD with Kent mutation Heteromer
NAG;CIT;CL;334-530
Assess
Crystal structure of synthetic nanobody (Sb14+Sb68) complexes with SARS-CoV-2 receptor binding doma… Heteromer
EDO;GOL;332-528
Assess
Nanobody H3 AND C1 bound to RBD Heteromer
NAG;CIT;CL;334-530
Assess
Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing human antibody… Heteromer
NAG;331-527
Assess
SARS-CoV-2 receptor binding domain in complex with WNb-2 Heteromer
NAG;PG4;331-527
Assess
Crystal structure of SARS-CoV-2 Spike RBD in complex with MW01 Fab Heteromer
CIT;NAG;334-530
Assess
Crystal structure of SARS-CoV-2 RBD in complex with a neutralizing antibody scFv Heteromer
CA;NAG;334-530
Assess
Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral … Heteromer
NAG;332-528
Assess
H11-D4, SARS-CoV-2 RBD, CR3022 ternary complex Heteromer
NAG;332-528
Assess
Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing human antibody… Heteromer
331-527
Assess
Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing human antibody… Heteromer
NAG;331-527
Assess
Crystal structure of receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with EY6A … Heteromer
NAG;PO4;333-529
Assess
Crystal structure of the SARS-CoV-2 receptor binding domain in complex with CR3022 Fab (crystal for… Heteromer
333-529
Assess
Cryo-EM structure of the SARS-CoV-2 N501Y mutant spike protein ectodomain bound to Fab ab1 (focused… Heteromer
NAG;332-528
Assess
Nanobody C5 bound to RBD Heteromer
NAG;ACT;332-527
Assess
Crystal structure of the SARS-CoV-2 receptor binding domain in complex with VNAR 3B4 Heteromer
NAG;EDO;334-529
Assess
Crystal structure of SARS-CoV-2 spike protein receptor-binding domain in complex with two cross-neu… Heteromer
NAG; 16×EDO;334-529
Assess
RBD domain of SARS-CoV2 in complex with neutralizing nanobody NM1226 Heteromer
NAG;PO4;PEG;332-527
Assess
Crystal structure of synthetic nanobody (Sb45) complexes with SARS-CoV-2 receptor binding domain Heteromer
333-528
Assess
SARS-CoV-2 receptor binding domain bound to Fab WCSL 129 and Fab PDI 93 Heteromer
NAG;GOL;332-527
Assess
Crystal structure of SARS-CoV-2 spike RBD in complex with human monoclonal antibody AZD8895 Heteromer
GOL;NAG;334-529
Assess
Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in a ternary comp… Heteromer
NAG;IMD;CL;GLU;GLY;PGE;GOL;PG4;333-528
Assess
Crystal Structure of COVID-19 virus spike receptor-binding domain complexed with a neutralizing ant… Heteromer
NAG;NI;EDO;332-527
Assess
Soaking competent crystal form of the SARS-CoV-2 Receptor Binding Domain (RBD):CR3022 complex. Heteromer
NAG;333-528
Assess
Structure of the SARS-CoV-2 RBD in complex with neutralizing antibodies BG4-25 and CR3022 Heteromer
NAG;333-528
Assess
Structure of SARS-CoV-2 spike receptor-binding domain complexed with high affinity ACE2 mutant 3N39 Heteromer
Q9BYF1;
NAG;NAG;NAG;NAG;ZN;SO4;332-527
Assess
Structure of the SARS-CoV-2 receptor binding domain in complex with the human neutralizing antibody… Heteromer
NAG;333-528
Assess
Crystal structure of SARS-CoV-2 Spike RBD in complex with MW06 Fab Heteromer
NAG;333-528
Assess
The SARS-CoV-2 spike protein receptor binding domain bound to neutralizing nanobodies WNb 2 and WNb… Heteromer
333-528
Assess
Cryo-EM structure of SARS-CoV-2 spike in complex with neutralizing antibody A23-58.1 that targets t… Heteromer
NAG;NAG;332-527
Assess
Cryo-EM structure of SARS-CoV-2 spike in complex with neutralizing antibody B1-182.1 that targets t… Heteromer
NAG;332-527
Assess
Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with C… Heteromer
NAG; 19×EDO;NO3;PEG;SO4;CL;333-527
Assess
H11-D4 complex with SARS-CoV-2 RBD Heteromer
NAG; 12×EDO;ACT;334-528
Assess
SARS-CoV-2 spike receptor-binding domain (RBD) in complex with S2X35 Fab and S309 Fab Heteromer
NAG; 23×SO4;GOL;CL;POL;333-527
Assess
Structure of COVID-19 virus spike receptor-binding domain complexed with a neutralizing antibody Heteromer
NAG;334-528
Assess
H11-H4 complex with SARS-CoV-2 Heteromer
NAG;SO4;334-528
Assess
Crystal structure of SARS-CoV-2 receptor binding domain complexed with nanobodies VHH E and U Heteromer
NAG;EDO;334-528
Assess
immune complex of SARS-CoV-2 RBD and cross-neutralizing antibody 6D6 Heteromer
NAG;333-527
Assess
Crystal structure of the SARS-CoV-2 receptor binding domain in complex with VNAR 2C02 Heteromer
EDO;NAG;CL;334-528
Assess
Crystal structure of the SARS-CoV-2 receptor binding domain in complex with the human neutralizing … Heteromer
NAG;333-527
Assess
Crystal structure of SARS-CoV-2 antibody P2C-1F11 with mutated RBD Heteromer
NAG;333-527
Assess
SARS-CoV-2 receptor binding domain bound to Fab WCSL 119 Heteromer
NAG;333-527
Assess
Structural basis for a germline-biased antibody response to SARS-CoV-2 (RBD:C1A-B12 Fab) Heteromer
NAG;334-528
Assess
Structural basis for a germline-biased antibody response to SARS-CoV-2 (RBD:C1A-F10 Fab) Heteromer
NAG;334-528
Assess
Structural basis for a germline-biased antibody response to SARS-CoV-2 (RBD:C1A-C2 Fab) Heteromer
NAG;334-528
Assess
Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with C… Heteromer
NAG;GOL;TRS;333-527
Assess
Crystal structure of SARS-CoV-2 RBD binding to pangolin ACE2 Heteromer
NAG;ZN;333-527
Assess
Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with C… Heteromer
NAG;GOL;CL;PG4;333-527
Assess
Structure of SARS-CoV-2 spike receptor-binding domain Y453F mutation complexed with human ACE2 Heteromer
Q9BYF1;
NAG;ZN;333-527
Assess
Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with C… Heteromer
NAG;GOL;FMT;333-527
Assess
Structure of novel coronavirus spike receptor-binding domain complexed with its receptor ACE2 Heteromer
Q9BYF1;
NAG;ZN;333-527
Assess
Crystal structure of the T478K mutant receptor binding domain of SARS-CoV-2 Spike glycoprotein in c… Heteromer
NAG;NAG;GOL;CL;333-527
Assess
Structure of the SARS-CoV-2 RBD in complex with neutralizing antibody C099 and CR3022 Heteromer
NAG;334-528
Assess
Crystal structure of synthetic nanobody (Sb16) complexes with SARS-CoV-2 receptor binding domain Heteromer
333-527
Assess
Structure of SARS-CoV-2 Beta variant spike receptor-binding domain complexed with human ACE2 Heteromer
Q9BYF1;
NAG;NAG;ZN;333-527
Assess
Crystal structure of SARS-CoV-2 receptor binding domain in complex with antibodies CC12.1 and CR3022 Heteromer
NAG;334-528
Assess
Crystal structure of SARS-CoV-2 spike protein receptor-binding domain complexed with a pre-pandemic… Heteromer
NAG;334-528
Assess
Structure of SARS-CoV-2 spike receptor-binding domain F486L mutation complexed with human ACE2 Heteromer
Q9BYF1;
NAG;ZN;333-527
Assess
Structure of sybody MR17 in complex with the SARS-CoV-2 S receptor-binding domain (RBD) Heteromer
NAG;GOL;333-527
Assess
Structural basis for a germline-biased antibody response to SARS-CoV-2 (RBD:C1A-B3 Fab) Heteromer
NAG;334-528
Assess
Structure of SARS-CoV-2 Gamma variant spike receptor-binding domain complexed with human ACE2 Heteromer
Q9BYF1;
NAG;NAG;ZN;333-527
Assess
Structure of SARS-CoV-2 Alpha variant spike receptor-binding domain complexed with human ACE2 Heteromer
Q9BYF1;
NAG;NAG;ZN;333-527
Assess
Molecular basis for a potent human neutralizing antibody targeting SARS-CoV-2 RBD Heteromer
NAG;333-527
Assess
Crystal structure of SARS-CoV-2 receptor binding domain in complex with antibodies CC12.3 and CR3022 Heteromer
NAG;334-528
Assess
Crystal structure of SARS-CoV-2 spike protein receptor-binding domain in complex with cross-neutral… Heteromer
NAG;334-528
Assess
Structure of sybody MR17-K99Y in complex with the SARS-CoV-2 S Receptor-binding domain (RBD) Heteromer
NAG;GOL;333-527
Assess
Crystal structure of SARS-CoV-2 receptor binding domain in complex with the Fab fragments of neutra… Heteromer
NAG;333-527
Assess
Crystal structure of SARS-CoV-2 RBD binding to dog ACE2 Heteromer
A0A5F4CXG9;
ZN;NAG;333-527
Assess
Crystal structure of SARS-CoV-2 spike RBD in complex with human monoclonal antibodies AZD8895 and A… Heteromer
PO4;NAG;333-527
Assess
Crystal structure of SARS-CoV-2 receptor binding domain in complex with human antibody CR3022 Heteromer
GOL;SO4;NAG;333-527
Assess
Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody CC12.1 Heteromer
NAG;334-528
Assess
Crystal structure of the receptor binding domain of SARS-CoV-2 P.1 variant Spike glycoprotein in co… Heteromer
Q9BYF1;
NAG;333-527
Assess
Structural basis for cross-species recognition of COVID-19 virus spike receptor binding domain to b… Heteromer
E2DHI3;
ZN;333-527
Assess
Crystal structure of SARS-CoV-2 Spike RBD in complex with MW05 Fab Heteromer
NAG;333-527
Assess
H11-D4, SARS-CoV-2 RBD, CR3022 ternary complex Heteromer
NAG;334-528
Assess
Ternary complex CR3022 H11-H4 and RBD (SARS-CoV-2) Heteromer
334-528
Assess
Crystal structure of SARS-CoV-2 receptor binding domain in complex with antibodies CV503 and COVA1-… Heteromer
NAG;333-527
Assess
SARS-CoV-2 receptor binding domain bound to Fab PDI 210 Heteromer
NAG;333-527
Assess
SARS-CoV-2 spike in complex with the S2A4 neutralizing antibody Fab fragment (local refinement of t… Heteromer
NAG;333-527
Assess
Cryo-EM structure of cat ACE2 and SARS-CoV-2 RBD Heteromer
Q56H28;
ZN;333-527
Assess
Structure of the SARS-CoV-2 spike S1 protein in complex with CR3022 Fab Heteromer
334-528
Assess
Cryo-EM structure of the SARS-CoV-2 N501Y mutant spike protein ectodomain bound to VH ab8 (focused … Heteromer
NAG;333-527
Assess
SARS-CoV-spike RBD bound to two neutralising nanobodies. Heteromer
NAG;334-528
Assess
Nanobody E bound to Spike-RBD in a localized reconstruction Heteromer
NAG;333-527
Assess
Complex of SARS-CoV-2 receptor binding domain with the Fab fragments of neutralizing antibodies REG… Heteromer
NAG;333-527
Assess
Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting no… Heteromer
334-528
Assess
SARS-CoV-2 Spike RBD in complex with neutralizing Fab 2H04 (local refinement) Heteromer
NAG;333-527
Assess
SARS-CoV-2 Spike RBD in complex with neutralizing Fab 2B04 (local refinement) Heteromer
NAG;333-527
Assess
Nanobody C5 bound to Kent variant RBD (N501Y) Heteromer
NAG;GOL;334-527
Assess
LY-CoV488 neutralizing antibody against SARS-CoV-2 Heteromer
NAG;GOL;PRO;334-527
Assess
LY-CoV481 neutralizing antibody against SARS-CoV-2 Heteromer
GOL;NAG;334-527
Assess
Crystal structure of the receptor binding domain of SARS-CoV-2 beta variant spike glycoprotein in c… Heteromer
NAG; 13×GOL; 14×CL; 14×K;TAR;333-526
Assess
SARS-CoV-2 receptor binding domain bound to Fab WCSL 129 Heteromer
NAG; 14×GOL;PG4;334-527
Assess
Crystal structure of the receptor binding domain of SARS-CoV-2 beta variant spike glycoprotein in c… Heteromer
NAG;CL;333-526
Assess
Crystal structure of the K417T mutant receptor binding domain of SARS-CoV-2 Spike glycoprotein in c… Heteromer
NAG;GOL;PEG; 12×SO4;CIT;CL;334-527
Assess
SARS-CoV-2 receptor binding domain bound to Fab PDI 42 Heteromer
NAG;GOL;334-527
Assess
Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with C… Heteromer
NAG;PEG;GOL;SO4;CL;TRS;334-527
Assess
Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody 47D1 Heteromer
NAG;NAG;334-527
Assess
Crystal structure of SARS-CoV-2 RBD in complex with a neutralizing antibody scFv Heteromer
NAG;334-527
Assess
Crystal structure of SARS-CoV-2 RBD in complex with a neutralizing antibody Fab Heteromer
NAG;334-527
Assess
Structure of sybody SR4 in complex with the SARS-CoV-2 S Receptor Binding domain (RBD) Heteromer
GOL;NAG;334-527
Assess
Crystal structure of SARS-CoV-2 receptor binding domain in complex with antibodies CV05-163 and CR3… Heteromer
NAG;334-527
Assess
SARS-CoV-2 receptor binding domain bound to Fab WCSL 129 and Fab PDI 96 Heteromer
NAG;MPD;GOL;334-527
Assess
Crystal structure of SARS-CoV-2 spike protein receptor-binding domain complexed with a pre-pandemic… Heteromer
NAG;EDO;SO4;PGE;334-527
Assess
Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing human antibody… Heteromer
NAG;GOL;334-527
Assess
Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with C… Heteromer
NAG;NO3;CL;334-527
Assess
Crystal structure of the SARS-CoV-2 RBD in complex with BD-236 Fab Heteromer
NAG;333-526
Assess
Crystal structure of the N501Y mutant receptor binding domain of SARS-CoV-2 Spike glycoprotein in c… Heteromer
10×SO4;GOL;NAG;PEG;CL;334-527
Assess
Crystal structure of SARS-CoV-2 antibody P22A-1D1 with RBD Heteromer
NAG;333-526
Assess
Crystal structure of the SARS-CoV-2 S RBD in complex with BD-623 Fab Heteromer
333-526
Assess
LY-CoV1404 neutralizing antibody against SARS-CoV-2 Heteromer
NAG;334-527
Assess
Crystal structure of SARS-CoV-2 spike receptor-binding domain bound with ACE2 Heteromer
Q9BYF1;
ZN;CL;NAG;333-526
Assess
SARS-CoV-2 receptor binding domain bound to Fab PDI 37 Heteromer
NAG;SO4;CL;GOL;334-527
Assess
Structure of SARS-CoV-2 spike receptor-binding domain in complex with high affinity ACE2 mutant (T2… Heteromer
Q9BYF1;
NAG;334-527
Assess
Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in a ternary comp… Heteromer
NAG;ACT;GOL;NAG;334-527
Assess
Crystal structure of SARS-CoV-2 antibody P5A-1D2 with RBD Heteromer
NAG;333-526
Assess
Crystal structure of synthetic nanobody (Sb45+Sb68) complexes with SARS-CoV-2 receptor binding doma… Heteromer
334-527
Assess
Crystal structure of receptor binding domain of SARS-CoV-2 Spike glycoprotein in ternary complex wi… Heteromer
NAG;CL;MG;333-526
Assess
Crystal structure of the SARS-CoV-2 RBD in complex with BD-604 Fab and BD-368-2 Fab Heteromer
333-526
Assess
Structure of SARS-CoV-2 spike receptor-binding domain in complex with high affinity ACE2 mutant (S1… Heteromer
Q9BYF1;
NAG;334-527
Assess
Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody CV07-… Heteromer
NAG;SO4;334-527
Assess
Crystal structure of SARS-CoV-2 receptor binding domain complexed with nanobody VHH W and antibody … Heteromer
NAG;334-527
Assess
crystal structure of SARS-CoV-2 antibody with RBD Heteromer
NAG;333-526
Assess
Crystal structure of the receptor binding domain of SARS-CoV-2 beta variant spike glycoprotein in c… Heteromer
NAG;SO4;333-526
Assess
Crystal structure of SARS-CoV-2 antibody P2C-1F11 with RBD Heteromer
NAG;333-526
Assess
SARS-CoV-2 receptor binding domain bound to Fab PDI 231 Heteromer
NAG;SO4;334-527
Assess
Crystal structure of the SARS-CoV-2 S RBD in complex with BD-515 Fab Heteromer
333-526
Assess
Crystal structure of SARS-CoV-2 RBD complexed with Nanosota-1 Heteromer
NAG;333-526
Assess
Crystal structure of the receptor binding domain of SARS-CoV-2 beta variant spike glycoprotein in c… Heteromer
NAG;NAG; 15×SO4;333-526
Assess
Crystal structure of the SARS-CoV-2 spike receptor-binding domain (RBD) with nanobody Nb20 Heteromer
CAC;334-527
Assess
Crystal structure of SARS-CoV-2 antibody P2C-1A3 with RBD Heteromer
NAG;333-526
Assess
Crystal structure of the SARS-CoV-2 RBD in complex with BD-236 Fab and BD-368-2 Fab Heteromer
333-526
Assess
Molecular basis for neutralizing antibody 2B11 targeting SARS-CoV-2 RBD Heteromer
333-526
Assess
Crystal structure of the receptor binding domain of SARS-CoV-2 beta variant spike glycoprotein in c… Heteromer
NAG;333-526
Assess
SARS-CoV-2 spike in complex with the S2E12 neutralizing antibody Fab fragment (local refinement of … Heteromer
NAG;334-527
Assess
Complex of SARS-CoV-2 receptor binding domain with the Fab fragments of two neutralizing antibodies Heteromer
NAG;333-526
Assess
SARS-CoV-2 spike protein RBD and P17 fab complex Heteromer
334-527
Assess
The interface of H014 Fab binds to SARS-CoV-2 S Heteromer
334-527
Assess
SARS-CoV-2 spike in complex with LCB3 (local refinement of the RBD and LCB3) Heteromer
NAG;334-527
Assess
The structure of FC08 Fab-hA.CE2-RBD complex Heteromer
Q9BYF1;
NAG;333-526
Assess
SARS-CoV-2 spike in complex with the CA521 neutralizing antibody Fab (focused refinement on Fab-RBD) Heteromer
NAG;333-526
Assess
Binding interface of SARS-CoV-2 RBD and its neutralizing antibody HB27 Heteromer
334-527
Assess
SARS-CoV-2 S bound to S2X259 Fab (local refinement of the RBD/S2X259 variable domains) Heteromer
NAG;334-527
Assess
CryoEM structure of SARS-CoV-2 RBD in complex with nanobodies Nb21 and Nb105 Heteromer
NAG;333-526
Assess
CryoEM structure of SARS-CoV-2 RBD in complex with nanobodies Nb17 and Nb105 Heteromer
333-526
Assess
CryoEM structure of SARS-CoV-2 RBD in complex with nanobodies Nb21 and Nb36 Heteromer
333-526
Assess
SARS-COV-2 Spike RBDMACSp36 binding to mACE2 Heteromer
Q8R0I0;
NAG;333-526
Assess
SARS-COV-2 Spike RBDMACSp25 binding to hACE2 Heteromer
Q9BYF1;
NAG;333-526
Assess
SARS-COV-2 Spike RBDMACSp36 binding to hACE2 Heteromer
Q9BYF1;
NAG;333-526
Assess
SARS-COV-2 Spike RBDMACSp6 binding to hACE2 Heteromer
Q9BYF1;
NAG;333-526
Assess
SARS-Cov-2 spike in complex with the Ab5 neutralizing antibody (focused refinement on Fab-RBD) Heteromer
NAG;333-526
Assess
SARS-CoV-2 spike in complex with the Ab4 neutralizing antibody (State 3) Heteromer
NAG;333-526
Assess
SARS-CoV-2 spike in complex with the Ab1 neutralizing antibody (focused refinement on Fab-RBD) Heteromer
NAG;333-526
Assess
SARS-CoV-2 receptor binding domain bound to Fab PDI 222 Heteromer
NAG;334-527
Assess
ACE2-RBD in SARS-CoV-2 Kappa variant S-ACE2 complex Heteromer
Q9BYF1;
ZN;NAG;333-526
Assess
Association of three complexes of largely structurally disordered Spike ectodomain with bound EY6A … Heteromer
NAG;333-526
Assess
Association of two complexes of largely structurally disordered Spike ectodomain with bound EY6A Fab Heteromer
NAG;333-526
Assess
Cryo-EM structure of SARS-CoV2 RBD-ACE2 complex Heteromer
Q9BYF1;
ZN;CL;NAG;333-526
Assess
SARS-CoV-2 Delta S-RBD-8D3 Heteromer
333-526
Assess
SARS-CoV-2 Delta S-RBD-ACE2 Heteromer
Q9BYF1;
333-526
Assess
ACE2-RBD in SARS-CoV-2 Beta variant S-ACE2 complex Heteromer
Q9BYF1;
ZN;NAG;333-526
Assess
Crystal Structure of SARS-CoV-2 S receptor-binding domain (RBD) in complex CoV11 Fab Heteromer
NAG;SO4;ACT;334-526
Assess
LY-CoV555 neutralizing antibody against SARS-CoV-2 Heteromer
GOL;334-526
Assess
Crystal structure of SARS-CoV-2 RBD in complex with a neutralizing antibody scFv Heteromer
NAG;335-527
Assess
Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with C… Heteromer
CL; 10×SO4;GOL;NAG;334-526
Assess
Crystal structure of the K417N mutant receptor binding domain of SARS-CoV-2 Spike glycoprotein in c… Heteromer
GOL;NAG; 13×SO4;CL;CIT;334-526
Assess
Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody COVA2… Heteromer
NAG;334-526
Assess
Crystal structure of the receptor binding domain of SARS-CoV-2 beta variant spike glycoprotein in c… Heteromer
NAG;GOL;CL;IOD;PEG;334-526
Assess
Crystal structure of the receptor binding domain of SARS-CoV-2 B.1.351 variant Spike glycoprotein i… Heteromer
19×SO4;GOL;NAG;PEG;334-526
Assess
Crystal structure of the receptor binding domain of SARS-CoV-2 P.1 variant Spike glycoprotein in co… Heteromer
15×SO4;GOL;NAG;PEG;334-526
Assess
Crystal structure of the SARS-CoV-2 S RBD in complex with BD-508 Fab Heteromer
334-526
Assess
Crystal structure of the receptor binding domain of SARS-CoV-2 beta variant spike glycoprotein in c… Heteromer
NAG;GOL; 14×SO4;PEG;333-525
Assess
Crystal structure of the receptor binding domain of SARS-CoV-2 beta variant spike glycoprotein in c… Heteromer
NAG;334-526
Assess
Crystal structure of FD20, a neutralizing single-chain variable fragment (scFv) in complex with SAR… Heteromer
NAG;334-526
Assess
Crystal structure of the receptor binding domain of SARS-CoV-2 beta variant spike glycoprotein in c… Heteromer
NAG;NAG;333-525
Assess
Crystal structure of the SARS-CoV-2 S RBD in complex with BD-604 Fab Heteromer
334-526
Assess
Crystal structure of affinity-enhancing and catalytically inactive ACE2 in complex with SARS-CoV-2 … Heteromer
Q9BYF1;
NAG;ZN;334-526
Assess
Crystal structure of the receptor binding domain of SARS-CoV-2 beta variant spike glycoprotein in c… Heteromer
334-526
Assess
SARS-CoV-2 spike in complex with LCB1 (local refinement of the RBD and LCB1) Heteromer
NAG;334-526
Assess
SARS-CoV-2 spike in complex with the S2D106 neutralizing antibody Fab fragment (local refinement of… Heteromer
NAG;335-527
Assess
SARS-CoV-2 receptor binding domain bound to Fab PDI 215 Heteromer
NAG;IPA;334-525
Assess
Crystal structure of SARS-CoV-2 receptor binding domain complexed with nanobody VHH V and antibody … Heteromer
NAG;334-525
Assess
Crystal structure of SARS-CoV-2 RBD in complex with antibody NT-193 Heteromer
NAG;334-525
Assess
Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1antibodies Heteromer
NAG;CL;334-525
Assess
ACE2-RBD Focused Refinement Using Symmetry Expansion of Applied C3 for Triple ACE2-bound SARS-CoV-2… Heteromer
Q9BYF1;
NAG;NAG;335-526
Assess
SARS-CoV-2 spike in complex with the S2K146 neutralizing antibody Fab fragment (local refinement of… Heteromer
NAG;335-526
Assess
Crystal structure of SARS-CoV-2 Spike RBD in complex with MW07 Fab Heteromer
NAG;336-526
Assess
Crystal structure of SARS-CoV-2 antibody P5A-3C8 with RBD Heteromer
NAG;333-522
Assess
Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody nCoV6… Heteromer
337-525
Assess
SARS-CoV-2 Spike RBD in complex with neutralizing Fab SARS2-38 (local refinement) Heteromer
NAG;333-520
Assess
Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with C… Heteromer
NAG;GOL;CL;PO4;PRO;334-519
Assess
Crystal structure of the L452R mutant receptor binding domain of SARS-CoV-2 Spike glycoprotein in c… Heteromer
NAG;NAG;GOL;PEG;CL;TRS;PO4;333-516
Assess
Structure of the SARS-CoV-2 receptor binding domain in complex with the human neutralizing antibody… Heteromer
NAG;334-517
Assess
Crystal structure of the SARS-CoV-2 RBD in complex with STE90-C11 Fab Heteromer
NAG;335-517
Assess
Crystal structure of the N501Y mutant receptor binding domain of SARS-CoV-2 Spike glycoprotein in c… Heteromer
NAG;GOL;SO4;334-516
Assess
Crystal structure of the SARS-CoV-2 S RBD in complex with BD-629 Fab Heteromer
334-516
Assess
Crystal structure of the SARS-CoV-2 S RBD in complex with BD-629 Fab and BD-368-2 Fab Heteromer
334-516
Assess
Crystallographic structure of neutralizing antibody 2-15 in complex with SARS-CoV-2 spike receptor-… Heteromer
336-518
Assess
Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in a ternary comp… Heteromer
NAG;NAG;GOL;ACT;334-516
Assess
The 2019-nCoV RBD/ACE2-B0AT1 complex Heteromer
Q695T7; Q9BYF1;
14×NAG;NAG; 10×NAG;LEU;ZN;336-518
Assess